Clinical Trials Logo

Conjunctivitis clinical trials

View clinical trials related to Conjunctivitis.

Filter by:

NCT ID: NCT05404932 Recruiting - Clinical trials for Plasminogen Deficiency

Treatment of Ligneous Conjunctivitis in Children With Plasminogen Deficiency

Start date: December 15, 2022
Phase: N/A
Study type: Interventional

Congenital plasminogen deficiency causes impaired wound healing and growth of pseudomembranous lesions over multiple parts of the body. The most common lesions involve eyes and are known as Ligneous conjunctivitis. These can cause scarring of the sclera, vision loss and even blindness. These pseudomembranous lesions are recur after surgical excisions, administration of intra-ocular cyclosporine, autologous serum drops or corticosteroids. Clinical data shows that these growths do not worsen and do not recur after administration of plasminogen (either as concentrate or as plasma) in the eyes, locally or intravenously. As plasminogen is not available as concentrate, we are using aliquoted allogenic plasma provided by Canadian Blood Services for intra-ocular application. These will be applied to eyes multiple times a day for a period of 2 to 6 months depending on disease severity and patient response. These may be used again if ligneous conjunctivitis recurs. The patient will be followed for a period of 2 years at least. All serious adverse events will be reported to Canadian Blood Services and Health Canada as appropriate.

NCT ID: NCT05400811 Not yet recruiting - Allergic Asthma Clinical Trials

Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis

Start date: December 2022
Phase: Phase 3
Study type: Interventional

Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and rhinitis/rhinoconjunctivitis (intermittent or persistent) allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae.

NCT ID: NCT05356793 Completed - Clinical trials for Acute Infectious Conjunctivitis (Disorder)

The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis

SCH1TAIC
Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy of Sasch1, a novel anti-infective eyedrop, in the treatment of acute infectious conjunctivitis.

NCT ID: NCT05314621 Completed - Clinical trials for Allergic Conjunctivitis

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis

Start date: December 31, 2021
Phase: Phase 4
Study type: Interventional

This is a single-center, randomized, double-masked, parallel study.

NCT ID: NCT05265910 Completed - Clinical trials for Allergic Conjunctivitis

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

Start date: December 14, 2021
Phase: Phase 4
Study type: Interventional

This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC model, a validated clinical model accepted by regulatory agents for assessing the efficacy of products on the signs and symptoms of allergic conjunctivitis.

NCT ID: NCT05263505 Terminated - Clinical trials for Mucous Membrane Pemphigoid

Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

Start date: February 21, 2022
Phase: Phase 2
Study type: Interventional

Ocular mucous membrane pemphigoid (MMP) is an autoimmune, scarring conjunctivitis that can lead to vision loss and permanent disability. It is a rare disorder with an estimated incidence of 1 in 60,000. There are currently no FDA-approved medications for the treatment of mucous membrane pemphigoid, highlighting a clear unmet need. At present, moderate to severe disease requires off-label use of potent immunosuppressive agents, such as oral anti-proliferatives (methotrexate, azathioprine, and mycophenolate), rituximab (RTX) or cyclophosphamide (CyC). Recently, Janus kinase (JAK) inhibition with baricitinib or tofacitinib been reported to be successful in one case of ocular MMP. This is a randomized, single-masked, two-arm study of baricitinib vs anti-proliferatives for ocular MMP.

NCT ID: NCT05234554 Completed - Clinical trials for Allergic Conjunctivitis

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Start date: January 21, 2022
Phase: Phase 3
Study type: Interventional

The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in subjects with seasonal allergic conjunctivitis using the environmental exposure chamber (EEC).

NCT ID: NCT05191186 Active, not recruiting - Allergic Asthma Clinical Trials

Documentation of Efficacy of Intralymphatic Allergen Immunotherapy

ILITNU
Start date: February 1, 2020
Phase: Phase 3
Study type: Interventional

Investigation of the clinical efficacy of 3 intralymphatic injections with grass pollen extract into inguinal lymph nodes on combined symptom-medication scores during grass pollen season in grass pollen allergic patients compared to placebo

NCT ID: NCT05186025 Active, not recruiting - Clinical trials for Allergic Conjunctivitis

Tyrosine Allergoid Paediatric and Adult Study

Start date: November 6, 2020
Phase:
Study type: Observational

The primary objective of this 5-year study is to demonstrate non-inferiority of children compared to adults by exploring long-term effectiveness after treatment with TA Bäume (trees) and TA Gräser (grass) following a perennial posology.

NCT ID: NCT05119920 Completed - Dry Eye Disease Clinical Trials

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

Start date: January 3, 2022
Phase: Phase 2
Study type: Interventional

This is a Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Signs and Symptoms of Dry Eye Disease.